Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(33%)
Results Posted
100%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_3
1
17%
Ph not_applicable
1
17%
Ph phase_2
2
33%
Ph phase_4
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

terminated117%
completed350%
recruiting233%

Recent Activity

Clinical Trials (6)

Drug Details

Intervention Type
PROCEDURE
Total Trials
6